Fintel reports that on April 8, 2025, Goldman Sachs upgraded their outlook for Eli Lilly and (NYSE:LLY) from Neutral to Buy.

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

Walgreens (WBA) stock is rising after the company reported better-than-expected second quarter earnings while preparing for ...

Goldman Sachs upgraded Eli Lilly (LLY) to Buy from Neutral with a price target of $888, down from $892, after assuming coverage of the name.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

An account that goes by the handle "Walter Bloomberg" shared a snippet that reportedly came from National Economic Council ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

After CMS excluded a Biden administration proposal for CMS to cover anti-obesity medications proposal from the final contract year 2026 ...

We recently published a list of Starter Stock Portfolio 12 Safe Stocks to Buy. In this article, we are going to take a look ...

That's why Veeva Systems should remain a leader in its niche and deliver excellent returns over the long run. It's a top stock to buy and hold for the next two decades.

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

This is CNBC’s coverage of how U.S. trade partners, industries and employers respond to President Donald Trump’s historic ...